tbuckley/cabot-search huggingface dataset:
Toward a Distinct Mental Disorder—Suicidal Behavior
Authors: Dominic Sisti, J. John Mann, Maria A. Oquendo
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
CLO20-047: Impact of Treating Physician on Late Treatment Related Morbidity – a Secondary Analysis of a Phase III Randomized Controlled Study in Localized Prostate Cancer
Authors: Shawn Malone, Scott Grimes, Soumyajit Roy
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-047: Impact of Treating Physician on Late Treatment Related Morbidity – a Secondary Analysis of a Phase III Randomized Controlled Study in Localized Prostate Cancer" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer
Authors: Chan Gao, Shangli Cai, Yong He
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
THE EFFECT OF COMPLEX CORONARY REVASCULARIZATION PROCEDURE IN PATIENTS AT HIGH-BLEEDING RISK
Authors: Ridhima Goel, Davide Cao, Roxana Mehran, Anastasios Roumeliotis, Rishi Chandiramani, Johny Nicolas, Samantha Sartori, Zaha Waseem, George D. Dangas, Usman Baber, Prakash Krishnan, Nitin Barman, Joseph Sweeny, Jason Kovacic, Vishal Kapur, Samin K. Sharma, Annapoorna Subhash Kini
Journal: Journal of the American College of Cardiology (2020)
Quality and Safety in Healthcare, Part LXVII
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2020)

There are many approaches to improving the well-being of medical students such as having a wellness curriculum including emphasizing the importance of keeping a balance in life between work and other activities, encouraging mindfulness and other stress reduction techniques, getting adequate sleep and exercise, and learning about the signs of burnout and depression. It is also important to have mentoring services and discussion groups available and to offer counseling for monetary management. Mental health services must be made available, and the students should be advised that seeking treatment will not adversely affect their ability to get a license or a good residency. The students should be counseled that being employed while in medical school is associated with a greater chance of burnout.
FLOW RESERVE ASSESSED BY FLOW RATE BUT NOT BY STROKE VOLUME PREDICTS MORTALITY IN LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS
Authors: Mohamed-Salah Annabi, Ezequiel Guzzetti, Bin Zhang, Jutta Bergler-Klein, Abdellaziz Dahou, Philipp E. Bartko, Ian G. Burwash, Stefan Orwat, Helmut Baumgartner, Julia Mascherbauer, Gerald Mundigler, Joao L. Cavalcante, Philippe Pibarot, Marie-Annick Clavel
Journal: Journal of the American College of Cardiology (2020)
Adenovirus-interferon γ (TG1042) demonstrates good tolerance and efficacy in relapsing primary cutaneous lymphoma (PCL): Final results of a phase I/II multicentric trial
Authors: M. Urosevic, S. Gellrich, B. Dreno, M. Schiller, O. Dereure, M. Baudard, M. Bagot, A. Khammari, P. Bleuzen, R. Dummer
Journal: Journal of Clinical Oncology (2006)

7539 Background: Interferons (IFNs), which can offset the Th2 dominance associated with PCL have been successfully used to treat these PCL. Intratumoral (i.t.) injection of TG1042 (a non-replicating recombinant adenovirus with a human IFNγ cDNA insert) induces high local production of IFNγ without severe toxicity associated with systemic delivery. Methods: We undertook a phase I/II multicentric trial of repeated, i.t. injections of TG1042 in patients with advanced primary T cell (CTCL) or B cell (CBCL) CL. One to 3 lesions were injected on day 1, 8, and 15 (a 4-week cycle) and thereafter up to 12 cycles. Immunohistochemistry and quantitative PCR were performed on injected lesions biopsied at baseline and after the 1st cycle. In the phase I, 18 patients were enrolled in 3 successive cohorts at the doses of 3 × 10 9 viral particles (vp) (n = 3), 3 × 10 10 vp (n = 3) and 3 × 10 11 vp (n = 12). In the phase II, 18 evaluable patients were planned to be treated at 3 × 10 11 vp. Results: To date, enrollment is complete, 39 patients (32 CTCL and 7 CBCL) have been included, 9 of them are still on treatment. Patients received a median of 4 lines of prior therapy. 11 patients were at stage Ib and 16 patients at higher stage. Altogether, 245 injections of TG1042 have been administered. Treatment was well tolerated with 8 grade 3 related adverse events. Injection site reaction and flu like syndrome are the most common adverse events. Histology demonstrates pronounced changes in infiltrate patterns with signs of vasculitis, increased numbers of eosinophils, neutrophils, CD8 and TIA-1+ve cells. CD4/CD8 ratio decreased in most tumors. Transgene-IFNγ mRNA was detected in injected lesions. Gene expression analysis of biopsies and PBMC shows up-regulation of IFNγ genes. Local clinical response has been observed in 17 (including 9 complete responses [CR]) out of 31 evaluable patients. 13 global responses (7 CR) out of 30 evaluable patients have been observed. All 5 evaluable CBCL responded (3 CR). Conclusions: These results demonstrate that TG1042 is well tolerated and presents a potential significant benefit for the treatment of both CTCL and CBCL. A phase II is planned in patients with CBCL to confirm those encouraging results. [Table: see text]
Evaluation of EZH2 SNPs in cholangiocarcinoma patients.
Authors: Elisa Paolicchi, Paola Pacetti, Elisa Giovannetti, Andrea Mambrini, Massimo Orlandi, Francesco Crea, Roberta Tartarini, Enrico Vasile, Romano Danesi, Godefridus J Peters, Maurizio Cantore
Journal: Journal of Clinical Oncology (2012)

10611 Background: Cholangiocarcinoma (CCA) is an aggressive tumor arising from biliary tract epithelium.CCA is the second most common primary hepatic malignancy, with a progressive increasing incidence in western countries. Polycomb group protein Enhancer of Zeste homolog 2 (EZH2) is overexpressed in several human carcinomas, including CCA, where EZH2 overexpression is associated with tumor progression. The aim of this study is to evaluate the correlation between candidate EZH2 Single Nucleotide Polymorphisms (SNPs) with clinical outcome in CCA patients. Methods: Genomic DNA was extracted from blood samples of 75 patients [44 male and 31 female, with average age of 62.3 (range, 26-80 years)] affected by hystologically confirmed advanced CCA, treated with the epirubicin-cisplatin-xeloda (ECX) regimen. We performed an in silico characterization to select EZH2 SNPs (rs2302427 C/G, rs6464926 C/T, rs17171119 T/G and rs887569 C/T) from 26 EZH2 SNPs described previously. Genotyping was performed through Taqman PCR. Prognostic value of selected EZH2 SNPs was assesses by correlation with time to progression (TTP) and overall survival (OS). OS and TTP curves were obtained through Kaplan-Meier method, and comparison with survival distribution was evaluated with logrank test. Results: Through specific software (PROMO 3.0, MicroSNiper and Gene Card) we performed an in silico analysis based on functional characterization criteria (transcription factor binding-TFB, miRNA binding and missense mutations). We selected 4 EZH2 SNP alleles showing specific relevance in CCA because of their differential TFB affinity (PPARα/RXRα, E2F-1, Pax-5 and p53). The rs887569 C/T SNP was significantly associated with clinical outcome. The TT genotype predicted a significantly longer OS in CCA patients (TT vs CT-CC p=0.026). Moreover, the TT genotype showed a trend-like association with reduced risk of death (HR=0.59, 95%CI=0.33-1.05, p=0.075), at multivariate analysis. Conclusions: These results suggest the role of rs887569 EZH2 SNP as a possible predictive marker of OS in advanced CCA patients treated with ECX regimen, and offer a potential new tool for treatment optimization.
Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab)
Authors: S. Dawson, J. McKinley, M. Jenkins, S. McLachlan, G. Lindeman, M. Friedlander, J. Hopper, K. Phillips
Journal: Journal of Clinical Oncology (2006)

1020 Background: This study prospectively evaluated risk management practices of true BRCA1/2 negative women. Methods: A questionnaire was mailed to 471 non-carriers from mutation positive families 3 years after their enrolment in the kConFab breast cancer (BC) family cohort study. Women who had received their mutation result had pre-test counselling and result disclosure in one of 16 Family Cancer Clinics nationwide. Undertaking mammography more often than 2 yearly (Australian population guidelines), clinical breast examination (CBE) more often than yearly, breast self-examination (BSE) more often than monthly and any trans-vaginal ultrasound (TVU) or CA-125 was considered over screening. Linear logistic regression was used to identify factors (age, marital status, education, parity, ethnicity, place of residence, time since disclosure of result, family history) associated with over screening. Results: 347 women responded (74%); 260 were excluded from this analysis (self-reported not knowing their mutation status, 207; uninformative screening data due to proximity of result disclosure to questionnaire administration, 47; developed cancer, 3; pregnancy, 3), leaving 87 subjects. Mean follow up was 4.4 years. Proportions over-screening were; mammography 53%, CBE 10%, BSE 11%, TVU 10% and CA125 10%. No measured factor was associated with over-utilization of BC screening. Women with &gt; one relative with OC were significantly more likely to over-utilize TVU (OR 8.1, CI 1.6–42 P=0.01) and CA125 (OR 19.6, CI 3.1–121 P=0.001) compared to women with ≤ one relative with OC. One woman underwent bilateral mastectomy and 1 bilateral oophorectomy; none used chemoprevention. Conclusions: A major benefit of learning one′s negative mutation status is that the intensity of risk management practices can be reduced to that appropriate for the general population. However, non-carriers with a strong family history of OC tend to inappropriately use OC screening. The reasons are unclear but need elucidation given the potential for harm. The reasons for over-utilization of mammography in 53% also warrant further study. No significant financial relationships to disclose.
CLO20-041: Prognostic Factors in Major Salivary Gland Tumors Treated with Adjuvant Radiation Therapy
Authors: Jung Julie Kang, Hannah Verma, Kaveh Zakeri, Huili Wang, Dan Fan, Ming Fan, Anna Lee, Sarin Kitpanit, Linda Chen, Yao Yu, C. Jillian Tsai, Sean McBride, Nadeem Riaz, Daphna Gelblum, Alan S. Ho, Eric Sherman, Lara Dunn, Jay O. Boyle, Richard J. Wong, Ian Ganly, Nancy Y. Lee
Journal: Journal of the National Comprehensive Cancer Network (2020)
CLO20-056: Real-Life Experience of Treatment With Anti-Programmed Cell Death-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) Antibodies in Patients With Non-Small Cells Lung Cancer (NSCLC)
Authors: Gianfranco Puppo, Gian Paolo Mattioli, Sara De Magistris, Erilda Kamberi, Maria Serafini, Giordano Riccioni, Yuri Rosati, Francesca Marchesani
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-056: Real-Life Experience of Treatment With Anti-Programmed Cell Death-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) Antibodies in Patients With Non-Small Cells Lung Cancer (NSCLC)" published on 20 Mar 2020 by National Comprehensive Cancer Network.
THE PREDICTIVE VALUE OF DIURETIC RESISTANCE AT THE TIME OF DISCHARGE FOR ACUTE HEART FAILURE
Authors: Suchapa Arayakarnkul, Thanaporn Ratchataswan, Thiratest Leesutipornchai, Aunchalee Jaroenlapnopparat, Palapun Waitayangkoon, Supanee Sinphurmsukskul, Aekarach Ariyachaipanich
Journal: Journal of the American College of Cardiology (2020)
Prevention of adverse events during treatment of HIV-associated Hodgkin lymphoma with ritonavir and zidovudine.
Authors: Sonia Sandhu, Shweta Gupta, Gail Itokazu, Tareq Braik, Shivi Jain, Audrey L. French, Paul G. Rubinstein
Journal: Journal of Clinical Oncology (2012)

8085 Background: In response to very high rates of neurologic and hematologic adverse events (AE) when ABVD was used in combination with ritonavir (RTV) or zidovudine (AZT) in HIV-associated Hodgkin (HL) we instituted a policy to use alternative antiretroviral agents during HL therapy in our HIV patients. In this study, we examined all AE in HIV-HL since the exclusion of RTV and AZT over 2 years ago. We also evaluated the AEs when HAART and chemotherapy for NHL were taken together in an expanded cohort of 52 pts. Methods: A screen of pharmacy and hospital databases between 1998-2012 identified all HIV-associated HL and NHL patients. Adverse events during chemotherapy were assessed by chart review and graded per the NCI Common Terminology Criteria for Adverse Events. Statistics: Fisher's exact test was used to examine the differences in AE incidence associated with use of specific antiretrovirals. Results: HAART use during chemotherapy was identified in 35/36 (96%) pts with HL and 52/108 (48%) of pts with NHL. Before RTV and AZT were prohibited, G3/4 neuropathy, neutropenia, and anemia developed in 31, 68, and 57% of 23 pts with HIV-HL respectively. Since then, 12 patients were treated with non-RTV and AZT based HAART. 0% neuropathy and only 20% G3/4 neutropenia and 10% anemia was observed, each statistically significant (p&lt;0.01). Of the 54 patients with NHL, 64% received CHOPR like, HYPERCVADR (18%), and daEPOCHR (11%). All AEs for each NHL regimen were similar to historical controls and no anti HIV medication was found to correlate with any AE, despite 28% of the HAART regimens containing RTV. Conclusions: No relationship between any AE and anti HIV medications was identified during treatment for NHL. But, excluding RTV or AZT-based HIV therapy during HL treatment, decreased neuropathy, neutropenia, and anemia by 100%, 38%, and 28% respectively. We suggest that exclusion of ritonavir and zidovudine from HAART regimens used with ABVD become the standard.
Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
Authors: Takahide Toyoda, Toshiko Kamata, Kazuhisa Tanaka, Fumie Ihara, Mariko Takami, Hidemi Suzuki, Takahiro Nakajima, Takayuki Ikeuchi, Yohei Kawasaki, Hideki Hanaoka, Toshinori Nakayama, Ichiro Yoshino, Shinichiro Motohashi
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Invariant natural killer T (iNKT) cells produce copious amounts of cytokines in response to specific glycolipid antigens such as α-galactosylceramide (αGalCer) presented by CD1d-expressing antigen-presenting cells (APCs), thus orchestrating other immune cells to fight tumors. Because of their ability to induce strong antitumor responses activated by αGalCer, iNKT cells have been studied for their application in cancer immunotherapy. In our previous phase I/II trial in non-small cell lung cancer (NSCLC) patients who had completed the standard treatment, we showed a relatively long median survival time without severe treatment-related adverse events. Based on these results, we performed a phase II trial to evaluate clinical responses, safety profiles and immune responses as a second-line treatment for advanced NSCLC. Methods Patients with advanced or recurrent NSCLC refractory to first-line chemotherapy were eligible. αGalCer-pulsed APCs were intravenously administered four times. Overall survival time was evaluated as the primary endpoint. The safety profile and immune responses after APC injection were also monitored. This study was an open label, single-arm, phase II clinical trial performed at Chiba University Hospital, Japan. Results Thirty-five patients were enrolled in this study, of which 32 (91.4%) completed the trial. No severe adverse events related to the treatment were observed. The estimated median survival time of the 35 cases was 21.9 months (95% CI, 14.8 to 26.0). One case (2.9%) showed a partial response, 14 cases (40.0%) remained as stable disease, and 19 cases (54.3%) were evaluated as progressive disease. The geometric mean number of iNKT cells in all cases was significantly decreased and the mean numbers of natural killer (NK) cells, interferon-γ-producing cells in response to αGalCer, and effector CD8+ T cells were significantly increased after the administration of αGalCer-pulsed APCs. Conclusions The intravenous administration of αGalCer-pulsed APCs was well-tolerated and was accompanied by prolonged overall survival. These results are encouraging and warrant further evaluation in a randomized phase III trial to demonstrate the survival benefit of this immunotherapy. Trial registration number UMIN000007321.
OLD DOG, NEW TRICK: NOVEL CT-DERIVED PARAMETER IS ASSOCIATED WITH LOW CARDIAC INDEX IN ACUTE PULMONARY EMBOLISM
Authors: Yevgeniy Brailovsky, Dalila Masic, Vladimir Lakhter, Fredrik Wexels, Sorcha Allen, Katerina Porcaro, Stephen Morris, Jeremiah Haines, Lucas Chan, Jawed Fareed, John Hibbeln, Amir Darki
Journal: Journal of the American College of Cardiology (2020)
30 DAY MORTALITY FOLLOWING ANDEXANET ALFA IN ANNEXA-4 COMPARED WITH PROTHROMBIN COMPLEX CONCENTRATE (PCC) THERAPY IN THE ORANGE STUDY FOR LIFE THREATENING NON-VITAMIN K ORAL ANTICOAGULANT (NOAC) RELATED BLEEDING
Authors: Alexander Thomas Cohen, Megan Lewis, Augusta Connor, Stuart Connolly, Patrick Yue, John Curnutte, Peter MacCallum, Joachim Tan, Laura Green
Journal: Journal of the American College of Cardiology (2020)
Correlations between depression according DSM-IV-TR (DSM) criteria, three validated scales, oncologist assessment, and clinical psychiatric interview in elderly advanced ovarian cancer (AOC) patients (pts): A GINECO study.
Authors: Marilène Filbet, Wadih Rhondali, Gilles Freyer, Virginie ADAM, Martine Dezerlle, Gaelle Abgrall-Barbry, Sophie Gobet-Bourcelot, Jean-Luc Machavoine, Muriel Chomat-Neyraud, Nicolas Gane, Pierre Saltel, Claire Falandry
Journal: Journal of Clinical Oncology (2012)

9080 Background: Depression is a major outcome in cancer pts. Clinicians typically rely on their clinical impression of depression rather than pts self-reports. Our aim was to explore the association between patient-reported depression, oncologist assessment (OA) and a clinical psychiatric interview (CPI) in elderly AOC pts. Methods: This analysis was a secondary endpoint of theElderly Women AOC trial, designed to assess the impact of geriatric covariates, notably depression, on survival in pts over 70 receiving 6 courses of carboplatin. Depression was assessed using the Geriatric Depression Scale-30 (GDS; cut off score of 10/30), the Hospital Anxiety Depression Scale (HADS; cut off score of 15/42), the distress thermometer (DT; cut off score of 4/10) and OA (yes/no). CPI was conducted by psychologists within 10 days after inclusion. The interview guide for CPI (yes/no) was constructed and adapted from three validated scale: GDS, Hamilton Depression Rating Scale Hamilton (HDRS), Montgomery Asberg Depression Rating Scale (MADRS) and the DSM criteria. DSM was considered as the gold standard. Results: Out of 111 pts, 100 (90.1 %) completed all the assessment (OA, GDS, HADS, DT, CPI). Patients characteristics were: mean age 78, performance status ≥2: 48 (55%). Thirty six pts (36%) were identified as depressed by the CPI versus 17 (17%) by OA, 32 (32%) by the GDS, 36 (36%) by the HADS, 58 (58%) by the DT and 16 (16%) according to DSM. We found a significant correlation between DSM and GDS (r=0.58; p&lt;0.001), DSM and CPI (r=0.53; p&lt;0.001). We did not find any significant correlation between DSM and OA (r=-0.05;p=0.733), DSM and DT (r=-0.07;p=0.583), and between DSM and HADS (r=0.127;p=0.258). Identification according to OA (yes/no) resulted in 87% false negatives and 18% false positives rates. The best sensitivity and specificity as a screening tool was found for GDS, 94% and 80% respectively. Conclusions: The use of validated tools such as GDS and a collaboration between psychologists and oncologists are warranted to better identify emotional disorders in elderly women with AOC.